Xbrane Biopharma AB (publ) ("Xbrane" or "the Company") (Nasdaq Stockholm: XBRANE) announces that Siavash Bashiri of Xbrane's management team have sold shares to pay back a loan that was taken in connection with the rights share issue in 2024 and which has matured. Siavash Bashiri has sold 14 733 shares and has a remaining ownership of 18 367 shares.
"The sale is made solely to repay the loan, and Siavash Bashiri's remaining holdings in Xbrane are still by far his largest private financial investment. Siavashs commitment and strong belief in Xbrane's future prospects remain," says Martin Åmark, CEO of Xbrane.
Contacts
Martin Åmark, CEO
E: martin.amark@xbrane.com
Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com
About Us
Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com
